| [1] |
Huang H, Ye Q, Xu Y, et al. Risk Factors and Clinical Features of Peripartum Cardiomyopathy in a Chinese Population[J]. J Multidiscip Healthc, 2024, 17:3763-3772. doi: 10.2147/JMDH.S468377.
|
| [2] |
Wang X, Zheng K, Zhang Q. Risk Factors for Peripartum Cardiomyopathy: A Systematic Review and Meta-Analysis[J]. Heart Lung Circ, 2025, 34(9):e125-e133. doi: 10.1016/j.hlc.2025.03.010.
|
| [3] |
Bak M, Youn JC, Bae DH, et al. Temporal Trends in Clinical Characteristics and Outcomes for Peripartum Cardiomyopathy: The Nationwide Multicenter Registry Over 20 Years[J]. J Am Heart Assoc, 2024, 13(13):e034055. doi: 10.1161/JAHA.123.034055.
|
| [4] |
Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy[J]. Eur J Heart Fail, 2019, 21(7):827-843. doi: 10.1002/ejhf.1493.
pmid: 31243866
|
| [5] |
Al Riyami N, Al Khayari S, Al Zadjali R, et al. Incidence, Risk Factors, Maternal and Neonatal Outcomes of Peripartum Cardiomyopathy (PPCM) in Oman[J]. Glob Heart, 2023, 18(1):23. doi: 10.5334/gh.1198.
pmid: 37153846
|
| [6] |
Honigberg MC, Givertz MM. Peripartum cardiomyopathy[J]. BMJ, 2019,364:k5287. doi: 10.1136/bmj.k5287.
|
| [7] |
Sigauke FR, Ntsinjana H, Tsabedze N. Peripartum cardiomyopathy: a comprehensive and contemporary review[J]. Heart Fail Rev, 2024, 29(6):1261-1278. doi: 10.1007/s10741-024-10435-5.
|
| [8] |
Sliwa K, Hilfiker-Kleiner D, Damasceno A, et al. Peripartum cardiomyopathy[J]. Lancet, 2025, 406(10518):2483-2493. doi: 10.1016/S0140-6736(25)01451-5.
|
| [9] |
Zhang Z, Zheng W, Chen M, et al. A new risk score for the assessment of outcomes for Chinese patients with peripartum cardiomyopathy[J]. Heart Lung, 2023, 60:81-86. doi: 10.1016/j.hrtlng.2023.02.021.
pmid: 36933287
|
| [10] |
Fu K, Zhang H, Chen N, et al. Risk factors for intracardiac thrombus in peripartum cardiomyopathy: a retrospective study in China[J]. ESC Heart Fail, 2023, 10(1):148-158. doi: 10.1002/ehf2.14158.
|
| [11] |
Cunningham FG, Byrne JJ, Nelson DB. Peripartum Cardiomyopathy[J]. Obstet Gynecol, 2019, 133(1):167-179. doi: 10.1097/AOG.0000000000003011.
pmid: 30575651
|
| [12] |
Attachaipanich T, Attachaipanich S, Kaewboot K. Efficacy and safety of bromocriptine in peripartum cardiomyopathy: A systematic review and meta-analysis[J]. Int J Cardiol, 2025, 427:133105. doi: 10.1016/j.ijcard.2025.133105.
|
| [13] |
van der Meer P, van Essen BJ, Viljoen C, et al. Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry[J]. Eur Heart J, 2025, 46(11):1017-1027. doi: 10.1093/eurheartj/ehae559.
|
| [14] |
Lang IM. What is new in the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy?[J]. Wien Klin Wochenschr, 2020, 132(3/4):69-72. doi: 10.1007/s00508-019-1529-y.
|